| Carvedilol is associated with improved survival in patients with cirrhosis: a long‐term follow‐up study HR McDowell, CS Chuah, D Tripathi, AJ Stanley, EH Forrest, PC Hayes Alimentary Pharmacology & Therapeutics 53 (4), 531-539, 2021 | 56 | 2021 |
| Real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease: the Scottish vedolizumab cohort N Plevris, CS Chuah, RM Allen, ID Arnott, PN Brennan, S Chaudhary, ... Journal of Crohn's and Colitis 13 (9), 1111-1120, 2019 | 48 | 2019 |
| Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with Crohn’s disease N Plevris, J Fulforth, M Lyons, SI Siakavellas, PW Jenkinson, CS Chuah, ... Clinical Gastroenterology and Hepatology 19 (9), 1835-1844. e6, 2021 | 35 | 2021 |
| Implementation of CT-P13 via a managed switch programme in Crohn’s disease: 12-month real-world outcomes N Plevris, GR Jones, PW Jenkinson, M Lyons, CS Chuah, LM Merchant, ... Digestive Diseases and Sciences 64, 1660-1667, 2019 | 35 | 2019 |
| Higher adalimumab drug levels during maintenance therapy for Crohn’s disease are associated with biologic remission N Plevris, M Lyons, PW Jenkinson, CS Chuah, LM Merchant, ... Inflammatory Bowel Diseases 25 (6), 1036-1043, 2019 | 29 | 2019 |
| Real‐world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort N Plevris, J Fulforth, S Siakavellas, A Robertson, R Hall, A Tyler, ... Journal of gastroenterology and hepatology 36 (8), 2067-2075, 2021 | 24 | 2021 |
| Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease N Plevris, PW Jenkinson, CS Chuah, M Lyons, LM Merchant, ... Frontline Gastroenterology 11 (2), 117-123, 2020 | 15 | 2020 |
| Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding—long‐term follow‐up of a randomised control trial PDJ Dunne, D Young, CS Chuah, PC Hayes, D Tripathi, J Leithead, ... Alimentary pharmacology & therapeutics 55 (12), 1581-1587, 2022 | 12 | 2022 |
| Hydrogen ion concentration and coronary artery bypass graft surgery with and without cardiopulmonary bypass CS Chuah, R Kirkbride, RP Alston, J Irons Journal of Cardiothoracic Surgery 8, 1-8, 2013 | 5 | 2013 |
| DOP87 multi-parameter datasets are required to identify the true prevalence of IBD: the Lothian IBD registry (LIBDR) GR Jones, M Lyons, N Plevris, P Jenkinson, C Bisset, J Fulforth, ... Journal of Crohn's and Colitis 13 (Supplement_1), S082-S083, 2019 | 4 | 2019 |
| Case of steroid-resistant Crohn’s-associated bronchiolitis in the setting of quiescent gastrointestinal disease treated with infliximab CS Chuah, C Noble, A Leitch BMJ Case Reports CP 11 (1), e226934, 2018 | 3 | 2018 |
| PWE-045 Vedolizumab results in reduced hospitalisation and steroid use over 1-year: Results from the Scottish Vedolizumab Cohort N Plevris, C Chuah, P Jenkinson, R Allen, P Baker, P Brennan, ... Gut 67 (Suppl 1), A89-A90, 2018 | 3 | 2018 |
| Circulating cell-free DNA in inflammatory bowel disease: liquid biopsies with mechanistic and translational implications CS Chuah, L Fischer, GT Ho Faculty Reviews 12, 2023 | 1 | 2023 |
| Neutrophil-dependent Mitochondrial DNA Release Associated With Extracellular Trap Formation in Inflammatory Bowel Disease B Drury, CS Chuah, R Hall, GR Hardisty, AG Rossi, GT Ho Gastro Hep Advances 2 (6), 788-798, 2023 | 1 | 2023 |
| non‐selective beta‐blockers in cirrhosis—effect beyond portal hypertension. Authors' reply. P Dunne, D Young, CS Chuah, P Hayes, D Tripathi, J Leithead, L Smith, ... Alimentary pharmacology & therapeutics 56 (1), 2022 | 1 | 2022 |
| Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn’s N Plevris, J Fulforth, P Jenkinson, M Lyons, C Chuah, S Siakavellas, ... | 1 | 2020 |
| P575 real-world effectiveness and safety of ustekinumab for the treatment of refractory Crohn’s disease: the scottish ustekinumab cohort N Plevris, A Robertson, J Fulforth, R Hall, I Campbell, C Kane, J Veryan, ... Journal of Crohn's and Colitis 14 (Supplement_1), S484-S484, 2020 | 1 | 2020 |
| Multi-parameter data-sets are required to identify the true prevalence of IBD: The Lothian IBD Registry (LIBDR) GR Jones, M Lyons, N Plevris, P Jenkinson, C Bisset, J Fulforth, ... JOURNAL OF CROHNS & COLITIS 13, S83-S83, 2019 | 1 | 2019 |
| DOP072 Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn’s disease cohort N Plevris, P Jenkinson, CS Chuah, M Lyons, R Hall, G Jones, E Watson, ... Journal of Crohn's and Colitis 12 (supplement_1), S079-S080, 2018 | 1 | 2018 |
| P70 High dimensional analysis of 2500 patient-reported outcomes as a scientific platform to study IBD-associated fatigue R Hall, R Whelan, SY Lau, M Halligan, C Mowat, JP Seenan, ... Gut 73 (Suppl 1), A90-A91, 2024 | | 2024 |
